Payment overview · 2025
General Payments
$19.89
1 reported records · 1 companies
Healthcare provider profile · identity verified
Scott Alan Beckstrand, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SIOUX FALLS, SD · NPI 1932173622
Verified facts
What the public records show
CMS Open Payments records show Scott Alan Beckstrand, MD received $19.89 in general payments during 2025 across 1 reported records.
Medtronic, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.89 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $19.89 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SPECIFY SURESCAN MRI 5-6-5 Normalized: specify surescan mri 5 6 5 |
Device | Medtronic, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 451 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 94 |
| Losartan Potassium | Losartan Potassium | 423 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 400 | 93 |
| Lisinopril | Lisinopril | 372 | 87 |
| Omeprazole | Omeprazole | 311 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 73 |
| Warfarin Sodium | Warfarin Sodium | 250 | 31 |
| Potassium Chloride | Potassium Chloride | 237 | 51 |
| Carvedilol | Carvedilol | 229 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 53 |
| Gabapentin | Gabapentin | 219 | 47 |
| Eliquis | Apixaban | 203 | 30 |
| Furosemide | Furosemide | 184 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 41 |
| Spironolactone | Spironolactone | 175 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 30 |
| Simvastatin | Simvastatin | 161 | 36 |
| Metformin Hcl Er | Metformin Hcl | 157 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 19 |
| Metformin Hcl | Metformin Hcl | 119 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 21 |
| Finasteride | Finasteride | 109 | 28 |
| Allopurinol | Allopurinol | 104 | 23 |
| Tramadol Hcl | Tramadol Hcl | 98 | 17 |
| Lorazepam | Lorazepam | 95 | 23 |
| Prednisone | Prednisone | 94 | 53 |
| Famotidine | Famotidine | 90 | 15 |
| Jardiance | Empagliflozin | 90 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 16 |
| Montelukast Sodium | Montelukast Sodium | 79 | 19 |
| Sertraline Hcl | Sertraline Hcl | 79 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 20 |
| Xarelto | Rivaroxaban | 77 | 12 |
| Clonazepam | Clonazepam | 75 | 15 |
| Alendronate Sodium | Alendronate Sodium | 71 | 17 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Mirtazapine | Mirtazapine | 62 | 13 |
| Glimepiride | Glimepiride | 59 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 54 | 15 |
| Synthroid | Levothyroxine Sodium | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 14 |
| Jantoven | Warfarin Sodium | 51 | suppressed |
| Nystatin | Nystatin | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 50 | suppressed |
| Meloxicam | Meloxicam | 49 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 48 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 13 |
| Fenofibrate | Fenofibrate | 47 | 13 |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Baclofen | Baclofen | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Atenolol | Atenolol | 42 | 11 |
| Bumetanide | Bumetanide | 41 | suppressed |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 11 |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19.89 · 1 records | Medtronic, Inc. | SPECIFY SURESCAN MRI 5-6-5 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error